Thyroid Eye Disease
Treatment of thyroid eye disease varies between North American, European providers
First-line treatment of thyroid eye disease differs around the globe, with teprotumumab the most commonly prescribed treatment in North America and IV steroids most common in Europe, according to a speaker.
Thyroid eye disease requires joint management with ophthalmologists
Not everyone can agree on what to call thyroid eye disease. For some, it is thyroid-associated ophthalmopathy; for others, it is thyroid-related immune orbitopathy. It has also been referred to as Graves’ orbitopathy.
Should teprotumumab become first-line therapy for thyroid eye disease?
Traditionally, many experts in the field have advocated steroids. More recently, EUGOGO and others have advocated high-dose pulse steroid therapy in TED as that route of administration appears to be less associated with side effects.
Teprotumumab effective, safe after 1 year in clinical use
Teprotumumab was approved for the treatment of thyroid eye disease in January 2020. As real-world experience with teprotumumab increases, several clinical reports describing patient responses, safety and effectiveness are now appearing.
Thyroid eye disease managed jointly by ophthalmologists and endocrinologists
Not everyone can agree on what to call thyroid eye disease.
Multidisciplinary management approach needed for thyroid eye disease
Thyroid eye disease was first described by Robert James Graves, FRCS, an Irish surgeon who recognized the association of hyperthyroidism with exophthalmos in 1835. Even today, many use Graves’ ophthalmopathy when discussing this disease.
VIDEO: Teprotumumab useful in patients with thyroid eye disease
WAILEA, Hawaii — In this video from Hawaiian Eye 2021, Roger A. Dailey, MD, discusses outcomes in patients treated for thyroid eye disease with traditional methods and teprotumumab.
VIDEO: Thyroid eye disease management changed with teprotumumab approval
WAILEA, Hawaii — In this video from Hawaiian Eye, Wendy W. Lee, MD, and Roger A. Dailey, MD, discuss the latest information surrounding diagnosis and management of thyroid eye disease.
Teprotumumab improves short- and long-term clinical outcomes in thyroid eye disease
Most adults with thyroid eye disease receiving an infusion of teprotumumab every 3 weeks for a 24-week period had a reduction of at least 2 mm in proptosis, with a long-term response observed in 67% of participants, according to study data.